Angelika Dobrieva

Hemogenyx Pharmaceuticals · Case study

Redesigning a listed biotech website for two opposite visitors

Hemogenyx develops therapies for blood and immune system diseases. It is publicly listed, so one site has to explain the science and serve the filings.

Role
UX/UI designer — end to end
Year
2023
Client
Hemogenyx Pharmaceuticals — New York biotech, publicly listed
My scope
Audit · Information architecture · Wireframes · Navigation · Visual system · Responsive UI · Handoff

01 — From One Audience to Two

One site, opposite intentions

An investor already knows which document they want. A reader knows nothing yet. The old navigation was built for neither.

Two arrivals

  • InvestorA document
  • ReaderAn explanation

The order I argued for

  • Structure
  • Navigation
  • Visual

A new visual language applied to the old architecture would only have made the same problem better-looking.

Designed for

  • Investor
  • Scientific reader
  • General reader

02 — From a Grown Site to a Mapped One

Pages, documents and other companies' websites

The site had grown rather than been designed. Three kinds of destination were linked identically, though each behaves differently once clicked.

Where a click lands

  • Internal pageStays on the site
  • PDF documentDownloads
  • External linkLeaves for LSE, ComputerShare

The rebuilt hierarchy

  • Site
    • Header
      • About
      • Technology
      • Clinical Need
      • News
      • Media
      • Investors
    • Footer
      • Contact
      • Join us
      • Privacy policy

Investor material

  • Eleven destinations
  • One Investors section
  • Governance
  • Advisers
  • Registrar
  • Shareholder information
  • Share data
  • Annual and half-year reports


04 — From a News Page to an Announcement Feed

One item, two things to do with it

A listed company publishes regulated announcements on a schedule. Each one is read by a journalist and filed by an investor, so each card carries both actions rather than making the visitor guess which link is which.

Every announcement

  • ReadStays on the site
  • PDFDownloads

The card

  • Date
  • Title
  • Two actions

The archive grows by a few dozen items a year and never shrinks, so the page is filtered by year rather than paginated — a shareholder looking for last year's AGM result picks the year, not a page number.

Holds without redesign

  • Four items in a year
  • Forty items in a year
  • A title of two words or twenty

05 — From Stock Imagery to a Subject

Imagery that argues for the science instead of decorating it

Before

  • Dense regulatory content
  • Generic stock photography
A visual language working against the science

The system

  • Visual system
    • A dark ground
      • Near-black at the top, brand red at the foot
    • Serif and sans in one line
      • Serif for the claim, sans for the fact
    • Navigation as pills
      • The only white shapes on the page
    • One motif
      • Soft-focus cell forms, hero and page headers only

The stock photography came out. The motif is used sparingly enough that it reads as subject matter rather than as decoration.

The same system carries

  • Tables for share data
  • A timeline for company history
  • Accordions for step-by-step science
  • Oversized page titles

06 — From Three Widths to Three Decisions

Deciding what breaks before it breaks

Three widths across the whole site, and three things worth deciding rather than discovering.

What had to be decided

  • SidebarNo room beside the content
  • Share tablesCannot be wide
  • Announcement gridBecomes one column

The fixed sidebar becomes a horizontal, swipeable section switcher, so the same orientation cue survives the small screen instead of collapsing into a hamburger.

Status

  • Delivered end to end
  • Structure before navigation before visual
  • Design outcomes, no post-launch analytics in scope
Next case
BAIT Biotechnology